PT-141 Overview
Mechanism of Action
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide analog of α-MSH activating melanocortin-4 receptors (MC4R) in the CNS. Unlike PDE5 inhibitors (sildenafil), which work peripherally on blood flow, PT-141 acts directly on brain pathways involved in sexual arousal. FDA-approved as Vyleesi for hypoactive sexual desire disorder.
~2.7 hours
Timing
30–60 min before anticipated activity
Injection Site
Subcutaneous, abdomen or thigh
Food
Light meal may help manage nausea
Common Stacks
- Not typically combined with other sexual health peptides
PT-141 Dosing Protocol
PRN Protocol
As needed1–2 mg SQ as needed
30–60 min before activity. Max 8 times/month.
PT-141 Expected Timeline
30–60 min
Onset of increased sexual desire/arousal
2–6 hours
Peak effects
12–24 hours
Effects resolve
PT-141 Side Effects
Nausea (~40%)
Flushing
Headache
Injection site reactions
Transient BP increase
PT-141 Research Studies
Bremelanotide for HSDD in premenopausal women (RECONNECT)
Kingsberg SA, Clayton AH, Pfaus JG, et al. — Obstet Gynecol (2019)
Pivotal phase 3 trial leading to FDA approval. Bremelanotide significantly improved sexual desire and reduced distress in premenopausal women with HSDD.
PubMed: 31764756PT-141 FAQ
How is PT-141 different from Viagra?
PT-141 works in the brain (melanocortin receptors) to increase desire and arousal. Viagra works peripherally to increase blood flow. They can potentially be used together.
Why does PT-141 cause nausea?
MC4R activation in brain regions regulating nausea. Typically improves with repeat use; start with 1 mg or take an antiemetic.